Combating rituximab resistance by inducing ceramide/lysosome-involved cell death through initiation of CD20-TNFR1 co-localization

References

• Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003; 14:520-35; PMID:12649096; http://dx.doi.org/10.1093/annonc/mdg175
   PubMed Web of Science ®Google Scholar
• Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program 2007; 2007:233-42; PMID:18024635; http://dx.doi.org/10.1182/asheducation-2007.1.233
   PubMedGoogle Scholar
• Czuczman MS, Olejniczak S, Gowda A, Kotowski A, Binder A, Kaur H, Knight J, Starostik P, Deans J, Hernandez-Ilizaliturri FJ. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008; 14:1561-70; PMID:18316581; http://dx.doi.org/10.1158/1078-0432.CCR-07-1254
   PubMed Web of Science ®Google Scholar
• Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007; 67:1270-81; PMID:17283164; http://dx.doi.org/10.1158/0008-5472.CAN-06-2184
   PubMed Web of Science ®Google Scholar
• Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with hemotherapy resistance resulting from decreased bax and bak expression. Clin Cancer Res 2008; 14:1550-60; PMID:18316580; http://dx.doi.org/10.1158/1078-0432.CCR-07-1255
   PubMed Web of Science ®Google Scholar
• Du J, Wang H, Zhong C, Peng B, Zhang M, Li B, Huo S, Guo Y, Ding J. Structural basis for recognition of CD20 by therapeutic antibody Rituximab. 2007; 282:15073-80; PMID:17395584
   PubMedGoogle Scholar
• Perosa F, Favoino E, Vicenti C, Guarnera A, Racanelli V, De Pinto V, Dammacco F. Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes. J Immunol 2009; 182:416-23; PMID:19109173; http://dx.doi.org/10.4049/jimmunol.182.1.416
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJM, Wiegman LJJM, van den Brakel JHN, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006; 177:362-71; PMID:16785532; http://dx.doi.org/10.4049/jimmunol.177.1.362
   PubMed Web of Science ®Google Scholar
• Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104:2635-42; PMID:15226177; http://dx.doi.org/10.1182/blood-2004-03-1110
   PubMed Web of Science ®Google Scholar
• Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44:3823-37; PMID:17768100; http://dx.doi.org/10.1016/j.molimm.2007.06.151
   PubMed Web of Science ®Google Scholar
• Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006; 103:4005-10; PMID:16537476; http://dx.doi.org/10.1073/pnas.0508123103
   PubMed Web of Science ®Google Scholar
• Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HTC, Beers SA, French RR, Cox KL, Davies AJ et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 2011; 118:2530-40; PMID:21768293; http://dx.doi.org/10.1182/blood-2011-01-330357
   PubMed Web of Science ®Google Scholar
• Bowles JA, Wang S-Y, Link BK, Allan B, Beuerlein G, Campbell M-A, Marquis D, Ondek B, Wooldridge JE, Smith BJ et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006; 108:2648-54; PMID:16825493; http://dx.doi.org/10.1182/blood-2006-04-020057
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754-8; PMID:11806974; http://dx.doi.org/10.1182/blood.V99.3.754
   PubMed Web of Science ®Google Scholar
• Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22:7359-68; PMID:14576843; http://dx.doi.org/10.1038/sj.onc.1206939
   PubMed Web of Science ®Google Scholar
• Liu Y, Shu L, Wu J. Ceramide participates in lysosome-mediated cell death induced by type II anti-CD20 monoclonal antibodies. Leuk Lymphoma 2015; 56:1863-8; PMID:25393677; http://dx.doi.org/10.3109/10428194.2014.981179
   PubMed Web of Science ®Google Scholar
• Ren H, Zhang C, Su L, Bi X, Wang C, Wang L, Wu B. Type II anti-CD20 mAb-induced lysosome mediated cell death is mediated through a ceramide-dependent pathway. Biochem Biophys Res Commun 2015; 457:572-7; PMID:25603047; http://dx.doi.org/10.1016/j.bbrc.2015.01.026
   PubMed Web of Science ®Google Scholar
• Petersen NHT, Olsen OD, Groth-Pedersen L, Ellegaard A-M, Bilgin M, Redmer S, Ostenfeld MS, Ulanet D, Dovmark TH, Lønborg A et al. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of Acid sphingomyelinase. Cancer Cell 2013; 24:379-93; PMID:24029234; http://dx.doi.org/10.1016/j.ccr.2013.08.003
   PubMed Web of Science ®Google Scholar
• Fehrenbacher N, Jäättelä M. Lysosomes as targets for cancer therapy. Cancer Res 2005; 65:2993-5; PMID:15833821
   PubMed Web of Science ®Google Scholar
• Mathiasen IS, Jäättelä M. Triggering caspase-independent cell death to combat cancer. Trends Mol Med 2002; 8:212-20; PMID:12067630; http://dx.doi.org/10.1016/S1471-4914(02)02328-6
   PubMed Web of Science ®Google Scholar
• Groth-Pedersen L, Jäättelä M. Combating apoptosis and multidrug resistant cancers by targeting lysosomes. Cancer Lett 2013; 332:265-74; PMID:20598437; http://dx.doi.org/10.1016/j.canlet.2010.05.021
   PubMed Web of Science ®Google Scholar
• Česen MH, Pegan K, Špes A, Turk B. Lysosomal pathways to cell death and their therapeutic applications. Exp Cell Res 2012; 318:1245-51; PMID:22465226; http://dx.doi.org/10.1016/j.yexcr.2012.03.005
   PubMed Web of Science ®Google Scholar
• Li B, Zhao L, Guo H, Wang C, Zhang X, Wu L, Chen L, Tong Q, Qian W, Wang H et al. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood 2009; 114:5007-15; PMID:19828699; http://dx.doi.org/10.1182/blood-2009-06-225474
   PubMed Web of Science ®Google Scholar
• Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CHT, Tutt A, Beers SA et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011; 117:4519-29; PMID:21378274; http://dx.doi.org/10.1182/blood-2010-07-296913
   PubMed Web of Science ®Google Scholar
• Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CHT, Klymenko T et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009; 119:2143-59; PMID:19620786
   PubMed Web of Science ®Google Scholar
• Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004; 4:604-16; PMID:15286740; http://dx.doi.org/10.1038/nrc1411
   PubMed Web of Science ®Google Scholar
• Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9:139-50; PMID:18216770; http://dx.doi.org/10.1038/nrm2329
   PubMed Web of Science ®Google Scholar
• Bielawska A, Crane HM, Liotta D, Obeid LM, Hannun YA. Selectivity of ceramide-mediated biology. Lack of activity of erythro-dihydroceramide. 1993; 268:26226-32; PMID:8253743
   PubMed Web of Science ®Google Scholar
• Kågedal K, Zhao M, Svensson I, Brunk UT. Sphingosine-induced apoptosis is dependent on lysosomal proteases. Biochem J 2001; 359:335-43; PMID:11583579; http://dx.doi.org/10.1042/bj3590335
   PubMed Web of Science ®Google Scholar
• Xu R, Sun W, Jin J, Obeid LM, Mao C. Role of alkaline ceramidases in the generation of sphingosine and its phosphate in erythrocytes. The FASEB Journal 2010; 24:2507-15; PMID:20207939; http://dx.doi.org/10.1096/fj.09-153635
   PubMed Web of Science ®Google Scholar
• Cheson BD, Cheson BD, Horning SJ, Horning SJ, Coiffier B, Shipp MA, Shipp MA, Fisher RI, Connors JM, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. 1999. page 1244
   Google Scholar
• Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, Kiyoi H, Kinoshita T, Naoe T. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood [Internet] 2009; 113:4885-93. Available from: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=19246561&retmode=ref&cmd=prlinks; PMID:19246561; http://dx.doi.org/10.1182/blood-2008-08-175208
   PubMed Web of Science ®Google Scholar
• Jilani I, O'Brien S, Manshuri T, Thomas DA, Thomazy VA, Imam M, Naeem S, Verstovsek S, Kantarjian H, Giles F et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003; 102:3514-20; PMID:12893761; http://dx.doi.org/10.1182/blood-2003-01-0055
   PubMed Web of Science ®Google Scholar
• Nakayama S, Yokote T, Tsuji M, Akioka T, Miyoshi T, Hirata Y, Hiraoka N, Iwaki K, Takayama A, Nishiwaki U et al. TNF-α receptor 1 expression predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified. Am J Surg Pathol 2014; 38:1138-46; PMID:24805855; http://dx.doi.org/10.1097/PAS.0000000000000094
   PubMed Web of Science ®Google Scholar
• Golay J, Bologna L, André P-A, Buchegger F, Mach JP, Boumsell L, Introna M. Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death. Blood 2010; 116:3372–3–authorreply3373-4; PMID:21030571; http://dx.doi.org/10.1182/blood-2010-06-289736
   PubMedGoogle Scholar
• Cragg MS, Alduaij W, Klein C, Umana P, Glennie MJ, Illidge TM. Response: novel lysosomal-dependent cell death following homotypic adhesion occurs within cell aggregates. Blood 2010; 116:3373-4; http://dx.doi.org/10.1182/blood-2010-07-291054
   Web of Science ®Google Scholar
• Morschhauser FA, Cartron G, Thieblemont C, Solal-Celigny P, Haioun C, Bouabdallah R, Feugier P, Bouabdallah K, Asikanius E, Lei G et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol [Internet] 2013; 31:2912-9. Available from: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.46.9585; PMID:23835718; http://dx.doi.org/10.1200/JCO.2012.46.9585
   PubMed Web of Science ®Google Scholar
• Lee H-Z, Miller BW, Kwitkowski VE, Ricci S, DelValle P, Saber H, Grillo J, Bullock J, Florian J, Mehrotra N et al. U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia. Clin Cancer Res 2014; 20:3902-7; PMID:24824310; http://dx.doi.org/10.1158/1078-0432.CCR-14-0516
   PubMed Web of Science ®Google Scholar
• Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393-402; PMID:20194898; http://dx.doi.org/10.1182/blood-2009-06-225979
   PubMed Web of Science ®Google Scholar
• Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, Klein C, Introna M. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 2013; 122:3482-91; PMID:24106207; http://dx.doi.org/10.1182/blood-2013-05-504043
   PubMed Web of Science ®Google Scholar
• Herter S, Birk MC, Klein C, Gerdes C, Umaña P, Bacac M. Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol 2014; 192:2252-60; PMID:24489098; http://dx.doi.org/10.4049/jimmunol.1301249
   PubMed Web of Science ®Google Scholar
• Tipton TRW, Roghanian A, Oldham RJ, Carter MJ, Cox KL, Mockridge CI, French RR, Dahal LN, Duriez PJ, Hargreaves PG et al. Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies. Blood 2015; 125:1901-9; PMID:25631769; http://dx.doi.org/10.1182/blood-2014-07-588376
   PubMed Web of Science ®Google Scholar
• Depoil D, Fleire S, Treanor BL, Weber M, Harwood NE, Marchbank KL, Tybulewicz VLJ, Batista FD. CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membrane-bound ligand. Nat Immunol 2008; 9:63-72; PMID:18059271; http://dx.doi.org/10.1038/ni1547
   PubMed Web of Science ®Google Scholar
• Gadella TW, Jovin TM. Oligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activation. J Cell Biol 1995; 129:1543-58; PMID:7790353; http://dx.doi.org/10.1083/jcb.129.6.1543
   PubMed Web of Science ®Google Scholar